Federal Register / Vol. 74, No. 124 / Tuesday, June 30, 2009 / Notices 31313 

Drug Schedule 

4-Bromo-2,5- 

dimethoxyphenethylamine 

(7392).

I 

4-Methyl-2,5- 

dimethoxyamphetamine (7395).

I 

2,5-Dimethoxyamphetamine 

(7396).

I 

2,5-Dimethoxy-4- 

ethylamphetamine (7399).

I 

3,4-Methylenedioxyamphetamine 

(7400).

I 

3,4-Methylenedioxy-Nethylamphetamine (7404).I 

3,4- 

Methylenedioxymethamphetamine (7405).

I 

4-Methoxyamphetamine (7411) .... I 

Dimethyltryptamine (7435) ............ I 

Psilocybin (7437) .......................... I 

Psilocyn (7438) ............................. I 

N-Benzylpiperazine (7493) ........... I 

Acetyldihydrocodeine (9051) ........ I 

Dihydromorphine (9145) ............... I 

Heroin (9200) ................................ I 

Normorphine (9313) ...................... I 

Pholcodine (9314) ......................... I 

Tilidine (9750) ............................... I 

3-Methylfentanyl (9813) ................ I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............. II 

Methylphenidate (1724) ................ II 

Amobarbital (2125) ....................... II 

Pentobarbital (2270) ..................... II 

Secobarbital (2315) ...................... II 

Phencyclidine (7471) .................... II 

Phenylacetone (8501) ................... II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................. II 

Benzoylecgonine (9180) ............... II 

Ethylmorphine (9190) ................... II 

Hydrocodone (9193) ..................... II 

Levorphanol (9220) ....................... II 

Meperidine (9230) ......................... II 

Methadone (9250) ........................ II 

Dextropropoxyphene, bulk.

(non-dosage forms) (9273) ........... II 

Morphine (9300) ........................... II 

Thebaine (9333) ........................... II 

Oxymorphone (9652) .................... II 

Alfentanil (9737) ............................ II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................. II 

The company plans to import 

analytical reference standards for 

distribution to its customers for research 

and analytical purposes. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a) 

and determined that the registration of 

Lipomed, Inc. to import the basic 

classes of controlled substances is 

consistent with the public interest and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971, at 

this time. DEA has investigated 

Lipomed, Inc. to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with State and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic classes of controlled 

substances listed. 

Dated: June 23, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–15445 Filed 6–29–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Registration 

By Notice dated February 23, 2009, 

and published in the Federal Register 

on March 2, 2009 (74 FR 9107), Sigma 

Aldrich Manufacturing LLC., 3500 

Dekalb Street, St. Louis, Missouri 63118, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) to be registered as an importer of 

the basic classes of controlled 

substances listed in schedules I and II: 

Drug Schedule 

Cathinone (1235) .......................... I 

Methcathinone (1237) ................... I 

Aminorex (1585) ........................... I 

Gamma Hydroxybutyric Acid 

(2010).

I 

Methaqualone (2565) .................... I 

Alpha-ethyltryptamine (7249) ........ I 

Ibogaine (7260) ............................. I 

Lysergic acid diethylamide (7315) I 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ...... I 

Mescaline (7381) .......................... I 

4-Bromo-2,5- 

dimethoxyamphetamine (7391).

I 

4-Bromo-2,5- 

dimethoxyphenethylamine 

(7392).

I 

4-Methyl-2,5- 

dimethoxyamphetamine (7395).

I 

2,5-Dimethoxyamphetamine 

(7396).

I 

3,4-Methylenedioxyamphetamine 

(7400).

I 

N-Hydroxy-3,4- 

methylenedioxyamphetamine 

(7402).

I 

3,4-Methylenedioxy-Nethylamphetamine (7404).I 

Drug Schedule 

3,4- 

Methylenedioxymethamphetamine (MDMA) (7405).

I 

4-Methoxyamphetamine (7411) .... I 

Bufotenine (7433) ......................... I 

Diethyltryptamine (7434) ............... I 

Dimethyltryptamine (7435) ............ I 

Psilocybin (7437) .......................... I 

Psilocyn (7438) ............................. I 

1-[1-(2- 

Thienyl)cyclohexyl]piperdine 

(7470).

I 

N-Benzylpiperazine (BZP) (7493) I 

Heroin (9200) ................................ I 

Normorphine (9313) ...................... I 

Etonitazene (9624) ....................... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............. II 

Methylphenidate (1724) ................ II 

Amobarbital (2125) ....................... II 

Pentobarbital (2270) ..................... II 

Secobarbital (2315) ...................... II 

Glutethimide (2550) ...................... II 

Nabilone (7379) ............................ II 

Phencyclidine (7471) .................... II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Diprenorphine (9058) .................... II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................. II 

Diphenoxylate (9170) .................... II 

Ecgonine (9180) ........................... II 

Ethylmorphine (9190) ................... II 

Hydrocodone (9193) ..................... II 

Levorphanol (9220) ....................... II 

Meperidine (9230) ......................... II 

Methadone (9250) ........................ II 

Morphine (9300) ........................... II 

Thebaine (9333) ........................... II 

Opium powdered (9639) ............... II 

Levo-alphacetylmethadol (9648) .. II 

Oxymorphone (9652) .................... II 

Fentanyl (9801) ............................. II 

The company plans to import the 

listed controlled substances for sale to 

research facilities for drug testing and 

analysis. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 952(a), 

and determined that the registration of 

Sigma Aldrich Manufacturing LLC., to 

import the basic classes of controlled 

substances is consistent with the public 

interest, and with United States 

obligations under international treaties, 

conventions, or protocols in effect on 

May 1, 1971, at this time. DEA has 

investigated Sigma Aldrich 

Manufacturing LLC., to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 952(a) 

and 958(a), and in accordance with 21 


sroberts on PROD1PC70 with NOTICES6
31314 Federal Register / Vol. 74, No. 124 / Tuesday, June 30, 2009 / Notices 

CFR 1301.34, the above named company 

is granted registration as an importer of 

the basic classes of controlled 

substances listed. 

Dated: June 23, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–15443 Filed 6–29–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on May 8, 2009, 

Chattem Chemicals Inc., 3801 St. Elmo 

Avenue, Building 18, Chattanooga, 

Tennessee 37409, made application by 

renewal to the Drug Enforcement 

Administration (DEA) as a bulk 

manufacturer of the basic classes of 

controlled substances listed in 

schedules I and II: 

Drug Schedule 

4–Methoxyamphetamine (7411) ... I 

Dihydromorphine (9145) ............... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............. II 

Lisdexamfetamine (1205) ............. II 

Methylphenidate (1724) ................ II 

Pentobarbital (2270) ..................... II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................. II 

Hydrocodone (9193) ..................... II 

Meperidine (9230) ......................... II 

Morphine (9300) ........................... II 

Oripavine (9330) ........................... II 

Thebaine (9333) ........................... II 

Oxymorphone (9652) .................... II 

Noroxymorphone (9668) ............... II 

Alfentanil (9737) ............................ II 

Remifentanil (9739) ...................... II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................. II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than August 31, 2009. 

Dated: June 22, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–15442 Filed 6–29–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated September 22, 2008, 

and published in the Federal Register 

on September 29, 2008, (73 FR 56612), 

Johnson Matthey Inc., Custom 

Pharmaceuticals Department, 2003 

Nolte Drive, West Deptford, New Jersey 

08066–1742, made application by letter 

to the Drug Enforcement Administration 

(DEA) to be registered as a bulk 

manufacturer of Gamma Hydroxybutyric 

Acid (2010), a basic class of controlled 

substance listed in schedule I. 

The company plans to produce 

sodium oxybate for sale to customers. 

One objection was received; however, 

the objector is not registered with DEA 

as a bulk manufacturer of Gamma 

Hydroxybutyric Acid (GHB). DEA has 

determined that the objection received 

is without merit and does not warrant 

denial of the application. DEA has also 

determined that the Food and Drug 

Administration does not preclude the 

sale of GHB to other manufacturers for 

the development of generic GHB 

products. 

DEA has considered the factors in 21 

U.S.C. 823(a) and determined that the 

registration of Johnson Matthey Inc. to 

manufacture the listed basic class of 

controlled substance is consistent with 

the public interest at this time. DEA has 

investigated Johnson Matthey Inc. to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic class of controlled substance 

listed. 

Dated: June 23, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–15447 Filed 6–29–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated June 19, 2008, and 

published in the Federal Register on 

June 27, 2008, (73 FR 36573), Norac 

Inc., 405 S. Motor Avenue, P.O. Box 

577, Azusa, California 91702–3232, 

made application by letter to the Drug 

Enforcement Administration (DEA) for 

registration as a bulk manufacturer of 

Gamma Hydroxybutyric Acid (2010), a 

basic class of controlled substance listed 

in schedule I. 

The company plans to manufacture 

the listed controlled substance in bulk 

for sale to its customers. 

One objection was received; however, 

the objector is not registered with DEA 

as a bulk manufacturer of Gamma 

Hydroxybutyric Acid (GHB). DEA has 

determined that the objection received 

is without merit and does not warrant 

denial of the application. DEA has also 

determined that the Food & Drug 

Administration does not preclude the 

sale of GHB to other manufacturers for 

the development of generic GHB 

products. 

DEA has considered the factors in 21 

U.S.C. 823(a) and determined that the 

registration of Norac Inc. to manufacture 

the listed basic class of controlled 

substance is consistent with the public 

interest at this time. DEA has 

investigated Norac Inc. to ensure that 

the company’s registration is consistent 

with the public interest. The 

investigation included the inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with State and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic class of controlled substance 

listed. 


sroberts on PROD1PC70 with NOTICES6